Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Radiotherapy in prostate cancer treatment: results of the patterns of care study in Korea

  • Chang, Ah Ram (Department of Radiation Oncology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine) ;
  • Park, Won (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2016.09.21
  • Accepted : 2017.02.13
  • Published : 2017.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The purpose of this study was to describe treatment patterns of radiotherapy (RT) for prostate cancer in Korea. Materials and Methods: A questionnaire about radiation treatment technique and principles in 2013 was sent to 83 radiation oncologists and data from 57 hospitals were collected analyzed to find patterns of RT for prostate cancer patients in Korea. Results: The number of patients with prostate cancer treated with definitive RT ranged from 1 to 72 per hospital in 2013. RT doses and target volumes increased according to risk groups but the range of radiation doses was wide (60 to 81.4 Gy) and the fraction size was diverse (1.8 to 5 Gy). Intensity-modulated radiation therapy was used for definitive treatment in 93.8% of hospitals. Hormonal therapy was integrated with radiation for intermediate (63.2%) and high risk patients (77.2%). Adjuvant RT after radical prostatectomy was performed in 46 hospitals (80.7%). Indications of adjuvant RT included positive resection margin, seminal vesicle invasion, and capsular invasion. The total dose for adjuvant RT ranged from 50 to 72 Gy in 24-39 fractions. Salvage RT was delivered with findings of consecutive elevations in prostate-specific antigen (PSA), PSA level over 0.2 ng/mL, or clinical recurrence. The total radiation doses ranged from 50 to 80 Gy with a range of 1.8 to 2.5 Gy per fraction for salvage RT. Conclusion: This nationwide patterns of care study suggests that variable radiation techniques and a diverse range of dose fractionation schemes are applied for prostate cancer treatment in Korea. Standard guidelines for RT in prostate cancer need to be developed.

Keywords

References

  1. Kim IH, Chie EK, Oh DH, et al. A web-based "patterns of care study" system for clinical radiation oncology in Korea: development, launching, and characteristics. J Korean Soc Ther Radiat Oncol 2003;21:291-8.
  2. Kim JH, Kim DY, Kim YH, et al. Survey on radiotherapy protocols for the rectal cancers among the Korean radiation oncologists in 2002 for the development of the patterns of care study of radiation therapy. J Korean Soc Ther Radiol Oncol 2003;21:44-53.
  3. Hur WJ, Choi Y, Lee HS, et al. Preliminary report of the 1998-1999 patterns of care study of radiation therapy for esophageal cancer in Korea. J Korean Soc Ther Radiol Oncol 2007;25:79-92.
  4. Suh CO, Shin HS, Cho JH, et al. The 1998, 1999 patterns of care study for breast irradiation after breast-conserving surgery in Korea. J Korean Soc Ther Radiol Oncol 2004;22:192-9.
  5. Keum KC, Shim SJ, Lee IJ, et al. The 1998, 1999 patterns of care study for breast irradiation after mastectomy in Korea. J Korean Soc Ther Radiol Oncol 2007;25:7-15.
  6. Kim JH, Kim JS, Ha SW, et al. A patterns of care study of the various radiation therapies for prostate cancer among Korean radiation oncologists in 2006. J Korean Soc Ther Radiol Oncol 2008;26:96-103. https://doi.org/10.3857/JKSTRO.2008.26.2.96
  7. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29. https://doi.org/10.3322/caac.21208
  8. Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat 2015;47:127-41. https://doi.org/10.4143/crt.2015.060
  9. Wang D, Ho A, Hamilton AS, et al. Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer. Radiat Oncol 2014;9:47. https://doi.org/10.1186/1748-717X-9-47
  10. Aneja S, Smith BD, Gross CP, et al. Geographic analysis of the radiation oncology workforce. Int J Radiat Oncol Biol Phys 2012;82:1723-9. https://doi.org/10.1016/j.ijrobp.2011.01.070
  11. Mahmood U, Levy LB, Nguyen PL, Lee AK, Kuban DA, Hoffman KE. Current clinical presentation and treatment of localized prostate cancer in the United States. J Urol 2014;192:1650-6. https://doi.org/10.1016/j.juro.2014.06.017
  12. Park J, Suh B, Shin DW, Hong JH, Ahn H. Changing patterns of primary treatment in Korean men with prostate cancer over 10 years: a nationwide population based study. Cancer Res Treat 2016;48:899-906. https://doi.org/10.4143/crt.2015.212
  13. Wang-Chesebro A, Xia P, Coleman J, Akazawa C, Roach M 3rd. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with threedimensional conformal radiation therapy in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2006;66:654-62. https://doi.org/10.1016/j.ijrobp.2006.05.037
  14. Beckendorf V, Guerif S, Le Prise E, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011;80:1056-63. https://doi.org/10.1016/j.ijrobp.2010.03.049
  15. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:1233-9. https://doi.org/10.1001/jama.294.10.1233
  16. Lawton CA, DeSilvio M, Roach M 3rd, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007;69:646-55. https://doi.org/10.1016/j.ijrobp.2007.04.003
  17. Pommier P, Chabaud S, Lagrange JL, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 2007;25:5366-73. https://doi.org/10.1200/JCO.2006.10.5171
  18. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911). Lancet 2005;366:572-8. https://doi.org/10.1016/S0140-6736(05)67101-2
  19. Denham JW, Joseph D, Lamb DS, et al. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. Lancet Oncol 2014;15:1076-89. https://doi.org/10.1016/S1470-2045(14)70328-6
  20. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52. https://doi.org/10.1016/S0360-3016(01)01579-6
  21. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005;6:841-50. https://doi.org/10.1016/S1470-2045(05)70348-X
  22. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516-27. https://doi.org/10.1056/NEJMoa0810095
  23. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26:2497-504. https://doi.org/10.1200/JCO.2007.14.9021
  24. Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011;12:451-9. https://doi.org/10.1016/S1470-2045(11)70063-8

Cited by

  1. Optimal collimator rotation based on the outline of multiple brain targets in VMAT vol.13, pp.None, 2017, https://doi.org/10.1186/s13014-018-1039-5
  2. The Treatments for Intermediate Risk Prostate Cancer vol.17, pp.1, 2017, https://doi.org/10.22465/kjuo.2019.17.1.22
  3. Elective pelvic irradiation in prostate cancer patients with biochemical failure following radical prostatectomy: A propensity score matching analysis vol.14, pp.4, 2017, https://doi.org/10.1371/journal.pone.0215057
  4. Prognostic significance of lymphovascular invasion in patients with prostate cancer treated with postoperative radiotherapy vol.37, pp.3, 2017, https://doi.org/10.3857/roj.2019.00332